Cinclus Pharma: Agreed paediatric study plan - Redeye

Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Investigation Plan (PIP) with EMA. While primarily being an important pre-requisite for marketing approval, we believe that this could also open the door for a potential label extension.

Länk till analysen i sin helhet: https://www.redeye.se/research/1049380/cinclus-pharma-agreed-paediatric-study-plan?utm_source=finwire&utm_medium=RSS